Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Prior Late-Stage Readout In Pemphigus Was A Setback
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
